Free Trial
NASDAQ:SYBX

Synlogic Q4 2023 Earnings Report

Synlogic logo
$1.47 +0.02 (+1.45%)
As of 08/29/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Synlogic EPS Results

Actual EPS
-$1.71
Consensus EPS
-$1.11
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A

Synlogic Revenue Results

Actual Revenue
$2.77 million
Expected Revenue
$2.71 million
Beat/Miss
Beat by +$60.00 thousand
YoY Revenue Growth
N/A

Synlogic Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 19, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Synlogic's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Synlogic Earnings Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX), a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

View Synlogic Profile

More Earnings Resources from MarketBeat